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Abstract. 
Diarrhea is a leading contributor to childhood morbidity and mortality in sub-Saharan Africa. Given the challenge of 
blinding most water, sanitation, and hygiene (WASH) interventions, diarrheal disease outcome measures in WASH 
intervention trials are subject to potential bias and misclassification. Using the platform of a cluster-randomized 
controlled trial of a household-based drinking water filter in western province, Rwanda, we assessed the impact of 
the drinking water filter on enteric seroconversion in young children as a health outcome and examined the 
association between serological responses and caregiver-reported diarrhea. Among the 2,179 children enrolled in the 
trial, 189 children 6–12 months of age were enrolled in a nested serology study. These children had their blood 
drawn at baseline and 6–12 months after the intervention was distributed. Multiplex serologic assays for Giardia, 
Cryptosporidium, Entamoeba histolytica, norovirus, Campylobacter, enterotoxigenic Escherichia coli and Vibrio 
cholerae were performed. Despite imperfect uptake, receipt of the water filter was associated with a significant 
decrease in seroprevalence of IgG directed against Cryptosporidium parvum Cp17 and Cp23 (relative risk [RR]: 
0.62, 95% confidence interval [CI]: 0.44–0.89). Serologic responses were positively associated with reported 
diarrhea in the previous 7 days for both Giardia intestinalis (RR: 1.94, 95% CI: 1.04–3.63) and C. parvum (RR: 
2.21, 95% CI: 1.09–4.50). Serological responses for all antigens generally increased in the follow-up round, rising 
sharply after 12 months of age. The water filter is associated with reduced serological responses against C. parvum, 
a proxy for exposure and infection; therefore, serological responses against protozoa may be a suitable health 
outcome measure for WASH trials among children with diarrhea. 
INTRODUCTION 
Diarrheal disease is the fourth leading contributor to global child mortality,1,2 due principally 
to unsafe water, poor sanitation, and hygiene.3 Young children aged 0–24 months are particularly 
vulnerable to severe diarrhea after initial exposure to specific pathogens, particularly after 6 
months of age when maternally acquired humoral immunity wanes.4 Diarrhea is associated with 
malnutrition and growth faltering,5–7 and poor nutritional status resulting from diarrhea places 
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young children at a higher risk of death. Diarrheal disease is a leading cause of morbidity and 
mortality in Rwanda,1,2 and environmental and demographic factors contribute to both diarrhea 
and stunting in the country.8 
Household water treatment (HWT) appears to be effective in reducing diarrheal disease 
among populations with unsafe sources of drinking water.9 Evidence of its effectiveness, 
however, is derived from nonblinded trials that report diarrheal disease as an outcome. Reported 
outcomes of water, sanitation, and hygiene (WASH) intervention trials, such as self-reported 
diarrheal disease, are subject to both recall and courtesy biases; such trials are highly subjective 
and unable to distinguish specific causal pathogens of the disease.10 Objective measures of 
exposures are particularly important in trials of environmental health interventions that cannot be 
blinded.11 
Objective outcome measures were incorporated in a recent meta-analysis of 54 studies 
examining the impact of WASH on intestinal protozoa infection, which found that the general 
availability and use of WASH interventions was associated with significantly lower odds of 
Entamoeba histolytica, Giardia intestinalis, and Cryptosporidium spp. infections. Diagnostics 
were typically performed with stool examination.12 Although stool assays offer an opportunity 
for more objective assessment, logistical constraints related to the storage, transport, and 
extensive laboratory work involved can limit their utility in resource-limited settings.13 In 
addition, the ability of stool assays to detect etiologic agents can be limited, as in the case of 
some protozoa, when cysts or oocysts are not continuously shed.14 Disease prevalence can also 
vary widely by season,15 so IgG/IgG4 assays can provide an additional means of ascertaining 
exposure retrospectively throughout the study period as opposed to using stool cultures, which 
may only detect pathogens that are present at the time of collection. 
Quantitative assays that detect serological IgG antibody responses against various 
enteropathogens can provide a useful measure of prior exposures to enteropathogens in children 
and may supplement relatively subjective caregiver-reported diarrheal disease outcomes.16 
Antibody responses that recognize some enteric pathogen antigens are transiently expressed, 
allowing researchers to infer some degree of temporality with regard to the timing of exposures, 
positive stools and, in some cases, the number of recent infections.17,18 For protozoan infections, 
cyst-positive stools appear to co-occur with serological responses to E. histolytica and Giardia 
intestinalis, with higher seroprevalence in children for whom stool samples were collected within 
1 week of serum collection versus 2 weeks or more,19 indicating that serological responses can 
be an indicator of recent protozoan infections. Antibody responses in cryptosporidiosis patients 
are consistently directed against 23- and 17-kDa Cryptosporidium parvum antigens (Cp23 and 
Cp17, respectively) and are known to have a 12-week half-life in adults.17 Immunoassays also 
provide the opportunity to characterize age-specific cumulative exposures to enteropathogens 
that can enhance epidemiological surveillance and inform etiology-specific interventions and 
regionally specific treatment strategies.20 Children under 24 months of age are the ideal 
population to examine seroconversion as maternally derived antibodies typically have waned13 
and initial exposure to enteropathogens often occurs within the first 2 years of life. 
Microsphere-based multiplex immunoassay methods allow for simultaneous measurement of 
antibodies against multiple antigens. Previously, this technology has been applied to neglected 
tropical disease surveillance, particularly those diseases targeted for global elimination.21 In 
recent years, single enzyme-linked immunosorbent assays and multiplex immunoassays have 
been shown to effectively target antigens of various enteropathogens,13,16–19,22,23 but the 
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technique’s incorporation into intervention trials has not been adequately explored. One trial16 
and a few cross-sectional or longitudinal population studies13,18,19,23,24 have incorporated this 
approach in the past, but have not included the full range of enteric antigens that are now 
currently available. 
We undertook this study in the context of a large-scale cluster-randomized controlled trial 
(CRT) described elsewhere.25 We aimed to assess the effectiveness of a point-of-use water filter 
on seroconversion against a panel of viral, bacterial, and protozoan enteropathogens among 
young children. We also sought to explore the potential for using serological response as an 
objective alternative to reported diarrhea to assess the effectiveness of water quality 
interventions, an approach that has been advocated in other serological studies.16,18 
METHODS 
Intervention. 
In an effort to reduce the high prevalence of waterborne disease in western province, 
Rwanda, DelAgua Health, Inc. (DelAgua) distributed point-of-use water filters to the poorest 
30% (Ubudehe 1 and 2) of households. The LifeStraw™ Family 2.1 filter employs a 0.2-m 
hollow-fiber ultrafiltration membrane designed to remove bacteria, parasites, and select viruses 
from source water. This system can filter up to 18,000 L of water, supplying a family of five 
with clean drinking water for 3–5 years.26 This system exceeds the World Health Organization’s 
“highly protective” standard for HWT technologies.27 Participating households also received an 
improved biomass cook stove. 
Study design. 
We assessed the effectiveness of the intervention by conducting a CRT in western province, 
Rwanda, using diarrhea in the previous 7 days as our primary outcome. The study design for the 
CRT has been described elsewhere25 and was informed by previously described pilot studies28,29 
and government-reported disease prevalence data.30 The intervention was delivered to all eligible 
households among 72 randomly selected sectors, with the remaining 24 sectors serving as 
controls. Outcomes for the sector-level study will be drawn from clinical records collected from 
all health clinics and community health workers in the study area. To assess coverage and use of 
the intervention, and to measure its impact on drinking water quality and other outcomes 
unavailable from health clinic records, we conducted a village-level study that consisted of 
intensive longitudinal data collection among households in 184 randomly selected villages 
divided equally among intervention and control sectors. For this nested village-level study, we 
sought to enroll up to 10 households with at least one child under 4 years old per village. We 
ultimately enrolled 1,582 total households with 2,179 children. Following a baseline conducted 
from late August through early December 2014, we conducted three follow-up rounds in the 
same households from February 2015 through March 2016. 
Enteric serological study. 
For this seroconversion substudy, we assessed serological responses against a panel of 12 
antigens representing nine of the most common causes of diarrhea in this region,31 relative to age 
and intervention status. Our enumerators were instructed to enroll all 6- to 12-month-old children 
residing in the households selected for intensive data collection during the baseline round of the 
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CRT. These children had one blood sample drawn at baseline and a second sample 
approximately 6–9 months later during follow-up. We conservatively estimated that 40% of 
children would seroconvert from negative to positive for C. parvum and norovirus antibody 
between baseline and follow-up in the absence of any intervention, based on a previous trial in 
Guatemala.16 If 87 children from each of our two study arms were enrolled in the study, we 
would have 80% power at  = 0.05 to detect a difference in seroconversion against any antigen 
of 40% versus 22.5% in our intervention and control groups. 
Between 3 and 6 small hanging drops of blood (10 L each for a total of 30–60 L) were 
collected on TropBio™ filter discs (Cellabs Pty Ltd., Brookvale, New South Wales, Australia) 
and kept in individual plastic resealable containers during the fieldwork. Immediately on return 
to the field office each day, the discs were placed on a table and allowed to dry overnight. The 
following morning, they were individually packaged in plastic resealable bags with desiccant, 
and were sent within 7 days of collection to the Rwanda National Reference Laboratory in 
Kigali, Rwanda, for long-term storage at 20°C. 
Laboratory methods. 
All laboratory analyses were performed at the Centers for Disease Control and Prevention 
(CDC) Infectious Disease Laboratories in Atlanta, GA. Total IgG responses against relevant 
enteropathogens were quantified using a multiplex SeroMAP™ microsphere-based 
immunoassay on the Luminex xMAP platform (Luminex Corp, Austin, TX). Antigens used in 
this assay were Schistosoma japonicum glutathione-S-transferase (GST) protein control24; 
Toxoplasma gondii surface antigen 2A gene/GST fusion (SAG2A)32; G. intestinalis variant-
specific surface protein AS8/GST fusion (VSP3)23,33 and variant-specific surface protein 
42e/GST fusion (VSP5)23,34; virus-like particles (VLPs) for three norovirus strains (Norwalk, 
Sydney and St. Cloud) kindly provided by Jan Vinje and Veronica Costantini (CDC); 
Campylobacter jejuni p39 antigen and Campylobacter p18 antigen35; Enterotoxigenic 
Escherichia coli (ETEC) heat-labile toxin  subunit (EtxB) (Sigma Chemical Co., St. Louis, 
MO); C. parvum 17-kDa protein/GST fusion (Cp17) and C. parvum 23-kDa protein/GST fusion 
(Cp23)23; cholera toxin  subunit (CtxB) (Sigma); and E. histolytica Gal/GalNAc lectin heavy 
chain subunit (LecA) (kindly provided by W. Petri, Univ. of Virginia School of Medicine).19,36 
The C. jejuni antigens were expressed as GST fusion proteins in pGEX-4T2 vector (GE 
Healthcare, Piscataway, NJ) using the same polymerase chain reaction (PCR) and directional 
cloning strategies as previously described for the T. gondii SAG2A protein.37 The forward and 
reverse deoxyoligonucleotides used in the PCR reactions were: 5-CGC GGA TCC GTT ATT 
AGT GGT TGT AGC AC-3 and 5-GCG GAA TTC TTA TCT TGA TAA TTT AAA TTC-3, 
respectively, for p18; and 5-CGC GGA TCC CCT GTA AGA TTT AGT TTA AAT C-3 and 
5-GCG GAA TTC TTA GTT TAA AGT ATA AAG CTT G-3, respectively, for p39. Proteins 
were expressed in E. coli Hb101 cells (Promega Corp., Madison, WI), purified on a glutathione 
Sepharose 4B affinity column (GE Healthcare) as directed by the manufacturer, and additionally 
purified by Mono Q chromatography (HR 5/5 column; GE Healthcare) using a 20-minute linear 
elution gradient of 0–0.6 M NaCl in 25 mM Tris (pH 7.5) at a flow rate of 1 mL/min. The 
proteins eluted at approximately 0.25 M NaCl on the gradient profile. Protein yield (BCA 
microassay; Pierce Chemical, Rockford, IL) was > 3 mg/L of culture. 
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Bead coupling. 
Procedures describing the coupling process of antigens to microspheres have been described 
in detail elsewhere.23,24 The carboxyl groups on each bead were esterified and then reacted with 
the primary amine groups of each antigen to bind the antigens to the microspheres through a 
covalent amide bond. Norovirus VLP antigens were coupled in buffer containing 10 mM 
Na2HPO4 and 0.85% NaCl at pH 7.2 (phosphate-buffered saline [PBS]) using 30 g protein/12.5 
× 106 beads. All other antigens used in this study were coupled in buffer containing 25 mM 2-(N-
morpholino)-ethanesulfonic acid and 0.85% NaCl at pH 5.0. The amounts of protein coupled to 
12.5 × 106 beads were GST control, 15 g; T. gondii SAG2A, 12.5 g; G. intestinalis VSP3 and 
VSP5, ETEC and cholera toxin  subunits, and E. histolytica LecA, 30 g; C. parvum Cp17, 6.8 
g; C. parvum Cp23, 12.5 g; C. jejuni p18 and p39, 25 g. Beads were quantified by a 
hemocytometer and stored at 4°C in PBS with 1.0% bovine serum albumin, 0.05% Tween 20 
and 0.02% sodium azide (NaN3) and the following protease inhibitors: 200 g of pefabloc (4-(2-
aminoethyl) benzenesulfonyl fluoride hydrochloride) (Roche Diagnostics, Indianapolis, IN), 200 
g ethylenediaminetetraacetic acid, and 1 g of both leupeptin and pepstatin A.19 
Serum preparation. 
The elution process loosely followed a protocol described elsewhere for antibody elution 
from the TropBio dried blood spots (DBSs).38 Elution buffer was made with 0.05% Tween-20 
and 0.05% NaN3 in PBS. DBS tabs were removed from 20°C, brought to room temperature, 
and submerged in 200 L of elution buffer for a minimum of 18 hours at 4°C. DBS tabs were 
considered acceptable for use if > 90% of the filter paper was red (indicative of saturation with 
10 uL of whole blood). Eluted serum (50 uL) was diluted into 450 uL of dilution buffer for a 
final serum dilution of 1:400 (assuming a hematocrit of 50%). Dilution buffer consisted of PBS 
with 0.50% polyvinyl alcohol (PVA), 0.80% polyvinylpyrrolidone (PVP), 0.50% casein, 0.30% 
Tween-20, and 0.02% NaN3, and E. coli extract at a final protein concentration of 3 g/mL. PVA 
and PVP were added to reduce background while not affecting specificity.19 
Multiplex bead assay. 
Multiplex assay conditions have previously been described.18,19 All samples were run in 
duplicate. Controls run on each 96-well plate included a buffer-only blank, one negative control, 
and five positive controls. The background from the buffer-only blank was subtracted from the 
result for each antigen, and values are reported as an average median fluorescent intensity with 
background subtracted (MFI-bg). A % coefficient of variation (%CV) was calculated from the 
duplicate well values, and samples were repeated if the %CV values for three or more positive 
responses exceeded 15% (N = 8). 
Cutoff determination. 
Cutoff values were previously established for C. parvum Cp17 and 23 using an receiver 
operating characteristic curve based on Western blot data22 and for G. intestinalis using the mean 
MFI-bg values plus three standard deviations of serum drawn from a panel of U.S. adults with no 
history of foreign travel. For the remaining antigens, cutoffs were determined through finite 
mixture models of two Gaussian distributions of continuous MFI values.20,39 Procedures for 
establishing cutoff values for seropositivity are described in further detail in the Supplemental 
Material. 
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Multiple imputation. 
To account for sample loss at baseline and follow-up, multiple imputation methods using 
fully conditional specification40 were used to impute missing values using predictors of diarrhea 
at baseline. These predictors were incorporated as potential covariates in individual models 
predicting MFI values for each antigen and were retained in imputation models if they were 
associated with antibody response at  = 0.35. This process generated 25 imputed datasets. 
Multiple imputation procedures are described in further detail in the Supplemental Methods. 
Statistical analysis. 
To assess the impact of the intervention on serological responses against the enteropathogen 
antigens explored in this study, we first performed a comparison for the continuous measures for 
antibody response (MFI) between intervention arms. For all antibodies assessed in this study, the 
serological responses as measured by MFI were not normally distributed. Goodness-of-fit tests 
were performed on all log-transformed values against a normal distribution to examine the 
appropriateness of applying a continuous MFI outcome variable for parametric analyses. If log-
transformed continuous variables fit a normal distribution, they were subject to linear regression. 
The change in log-transformed MFI between baseline and follow-up (MFI-bg) was compared 
between intervention and control groups using a t test with a pooled variance estimator where 
parametric analyses were possible. All variables that could not be transformed to fit a common 
statistical distribution were only analyzed for serological response relative to their cutoff values. 
Seroconversion and prevalence of serological responses against enteropathogens in this study 
were calculated using both available and imputed data. MFI-bg data for each antigen were 
dichotomized above and below their respective cutoff points at baseline and follow-up. Binary 
seroprevalence estimates were calculated among children in households randomized to 
intervention households and compared with children in control households using log binomial 
models on both observed and imputed data.41 Village-level clustering was accounted for through 
robust variance estimation; for imputed data, generalized estimating equation (GEE) parameter 
estimates with empirical standard errors were calculated and combined to generate valid 
statistical inferences of the associations under study.42 For seroconversion analyses, a child was 
considered to have seroconverted against a particular antigen if their MFI-bg values were below 
the cutoff at baseline but above the cutoff at follow-up. Seroconversion prevalence was 
compared with both observed and imputed data between intervention and control groups using 
log binomial models with robust variance estimation to account for intra-village clustering to 
calculate the relative risk of seroconversion at follow-up against any specific antigen among 
children in the intervention versus control arm. Models were selected using backward selection 
procedures in which the full model included age, gender, socioeconomic status, time between 
rounds, water source type, toilet type, toilet area cleanliness, and shared sanitation. 
Socioeconomic status was considered as a confounder and determined by an index calculated 
through a principal components analysis using polychoric correlations of discrete household 
asset variables,43,44 as described in further detail in the Supplemental Methods. Confounders 
were retained if they altered the effect size from the full model by more than 10%, and effect 
modifiers were considered if the magnitude or direction of the relationship between an exposure 
and the serological outcome varied substantially by level of the modifier. Final models for each 
serological outcome of interest are shown in Supplemental Table 4; we assessed confounding by 
other demographic, water, and sanitation factors when deemed appropriate by our model 
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selection procedures, even though we found reasonable balance between study arms on most 
household and environmental factors collected at baseline (Table 1). Both unadjusted and 
adjusted log binomial models were run using observed and imputed data. 
To assess the utility of serological testing as an objective alternative to reported diarrhea, 
dichotomized MFI-bg values representing seroprevalence of antibody responses against each 
antigen were assessed relative to diarrhea prevalence among all children, with data combined 
between baseline and follow-up. On the day of the blood draw, survey respondents were asked to 
recall whether the child had experienced diarrhea as per the World Health Organization case 
definition (passage of three or more loose or water stools within 24 hours45) within the previous 
7 days. The relative risk for diarrheal disease in the previous 7 days in seropositive versus 
seronegative children was compared for each antigen of interest using repeated measures log 
binomial models with robust error variance estimation to account for separate measurements 
taken for each individual child at both baseline and follow-up. To obtain the approximate age of 
seroconversion against these enteric targets in this population, age-specific MFI-bg values 
reflecting level of IgG produced were plotted by 3-month age group. All analyses were 
performed using SAS V9 (SAS Institute, Cary, NC). 
Ethical approval. 
Informed consent was obtained both in writing and verbally. The study protocol and survey 
instruments were reviewed and approved by the Emory University Institutional Review Board 
(Ref no. 73615), the London School of Hygiene and Tropical Medicine Research Ethics 
Committee (Ref no. 7711), the Rwandan National Ethics Committee (Ref no. 1497), and the 
National Health Research Committee of Rwanda (Ref no. NHRC/2014/PROT/0163). The CRT 
is registered at Clinicaltrials.gov (NCT02239250). 
RESULTS 
Samples analyzed. 
Out of the 251 children who met our age eligibility criteria for enrollment in this 
seroconversion substudy, 189 children who were 6–12 months old at baseline were ultimately 
enrolled. A summary of the sample flow and loss is depicted in Figure 1, which is further divided 
into intervention and control arms in Supplemental Table 1 and 2 for baseline and follow-up. 
Children were not enrolled if their caregiver did not consent to the blood draw (17%), the child 
was not at home during the baseline assessment (6%), or if the child was too ill to participate 
(1%). Of these 189 children, 153 children were available at follow-up; loss to follow-up (19%) 
was due to refusals (3%), unsuccessful draws (1%), unavailability of the child (11%), or child 
illness (5%). Among the 189 children enrolled at baseline, 120 baseline samples, 152 follow-up 
samples, and 97 paired samples from baseline and follow-up were available for analysis. 
Samples were deemed insufficient for analysis if spots were less than approximately 90% filled. 
Descriptive statistics of child and household water and sanitation characteristics at baseline 
demonstrated reasonable balance between intervention and control groups (Table 1). 
Continuous serological analyses. 
MFI-bg values for all norovirus antigens, T. gondii SAG2A, all C. parvum antigens, and C. 
jejuni p18 were successfully log-transformed to fit a normal distribution. Serological responses 
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against C. parvum Cp17 at follow-up were significantly lower in the intervention group than the 
control group (t = 2.00, P = 0.047), but the change in log-transformed mean MFI-bg from 
baseline to follow-up (MFI-bg) did not significantly differ between the two groups. Mean 
responses in log-transformed MFI values for C. parvum Cp23 did not significantly differ 
between the two intervention arms. There was no statistical difference in serologic response, as 
measured by median MFI-bg at follow-up and MFI-bg, between intervention and control 
groups when examining serological responses against antigens for norovirus or C. jejuni. No 
child appeared to produce any serological response to T. gondii SAG2A throughout the course of 
the study; therefore, this antigen was dropped from subsequent analyses. Median responses 
against C. jejuni p39, G. intestinalis VSP3 and VSP5, E. histolytica LecA, and EtxB and CtxB 
could not be transformed; therefore, responses to these antigens were only examined using 
binomial variables derived from threshold cutoffs. Median serological responses at baseline and 
follow-up for all antigens are plotted in Figure 1 and are depicted in Figure 2. 
Serological responses by age. 
Age-specific median serological responses to all enteric antigens assessed in this study are 
displayed in Figure 3. Although children began expressing antibodies to EtxB and CtxB at early 
ages, the children in our study generally did not begin to produce antibodies against all other 
antigens until after 12 months of age. E. histolytica responses remained markedly low throughout 
the study period, and responses to T. gondii SAG2A were negligible. Antibody responses against 
Norwalk, Cp17, and Cp23 peaked between 12 and 20 months of age. Serological responses 
against G. intestinalis VSP3 and VSP5 increased sharply after 12 months of age and remained 
elevated through 18 months of age (Figure 3). 
Impact of intervention on serologic responses. 
Analyses were performed using both observed (Tables 3 and 4) and imputed data 
(Supplemental Table 3) to calculate relative risks of both seroprevalence at follow-up and 
seroconversion between baseline and follow-up for all enteric antigens in this study. Any 
correlation between baseline and follow-up measures could indicate the potential for residual 
expression of antibody spanning both study rounds. To account for any differences in antibody 
production between the two study arms at baseline, we opted to measure both 1) raw 
seroprevalence against all antigens at follow-up (Table 3) and 2) seroconversion, measured as 
seroprevalence at follow-up among children who were seronegative at baseline (Table 4). 
Relative risk estimates were comparable for imputed and observed data (Tables 3 and 4 and 
Supplemental Table 3). Seroprevalence of paired C. parvum Cp17 + Cp23 antibodies at follow-
up was markedly reduced by 38% among children in the intervention group (adjusted risk ratio 
[aRR]: 0.62, 95% confidence interval [CI]: 0.44–0.89) (Table 3), although no significant 
difference was observed in seroconversion (aRR: 0.59, 95% CI: 0.33–1.07) (Table 4). The 
intervention did not significantly affect seroprevalence or seroconversion of antibody responses 
against norovirus antigens, G. intestinalis VSPs, E. histolytica LecA antigen, C. jejuni p18 and 
p39 antigens, or EtxB and CtxB. 
Association between seroprevalence against enteropathogens and diarrhea. 
Seven-day prevalence of diarrheal disease doubled in children with positive serological 
responses against both Giardia VSP antigens (aRR: 1.94, 95% CI: 1.04–3.63) and among 
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children with seropositivity against both C. parvum antigens (aRR: 2.21, 95% CI: 1.09–4.50). 
Serological responses against C. jejuni p18 and p39, E. histolytica LecA, any norovirus VLP, 
and EtxB and CtxB were not associated with diarrhea prevalence (Table 5). 
DISCUSSION 
This study demonstrates the potential for the LifeStraw Family 2.1 water filter to confer a 
protective benefit against enteropathogen exposure in children under 2 years of age. Children 
who resided in households that received the water filter were significantly less likely to be 
seropositive against C. parvum at follow-up than children in the control group. No significant 
effect was observed for the other enteropathogens explored in this study, indicating that other 
sources of contamination may be present to counteract some of the protective benefit conferred 
by the filter. Given recent findings that cases of moderate-to-severe diarrhea attributed to 
Cryptosporidium infection in children 12–23 months old are associated with a higher risk of 
death,31 the water filter’s impact on reducing cumulative exposures to this pathogen is in line 
with priorities to prevent cryptosporidiosis among children in this age group in resource-limited 
settings.31 
Examination of age-specific MFI-bg values for each pathogen indicated that the age group 
targeted by this serological study was suitable for examination of enteropathogen seroconversion 
relative to receipt of this water filter intervention. Median MFI values for all pathogens generally 
did not increase until after 12 months, with the notable exception of EtxB and CtxB, for which 
median MFI values are elevated even in the first year of life. This comports with the findings of 
the Global Enteric Multicenter Study (GEMS), which indicated that ETEC was the third leading 
pathogen associated with moderate-to-severe diarrhea among children 0–11 months old.31 
Median MFI-bg values for G. intestinalis VSP3 and VSP5 antigens remained relatively low 
throughout the study period, but box plots depicting log-transformed MFI values relative to age 
group indicated that serological responses against VSP3 and VSP5 broadly increased after 12 
months of age (Figure 4). This indicates that childhood exposure to certain waterborne protozoa, 
such as Giardia, may increase substantially in the immediate postweaning period. 
Parametric analyses yielded significantly lower serological responses against C. parvum 
Cp17 at follow-up, but no statistically significant differences were observed after subtracting 
responses observed at baseline. Similarly, Cp17 seroprevalence at follow-up, designated as 
serological responses falling above the cutoff point, was significantly higher in the control group 
than the intervention group; however, no statistically significant difference in seroconversion 
was observed. Since seroconversion analyses rely on a subset of the population who were 
seronegative at baseline, the study power of the seroconversion analyses could have been 
compromised. 
Serological responses to G. intestinalis and C. parvum were associated with diarrheal disease 
in the previous 7 days, lending further support to the potential utility of serological assays as an 
objective method to evaluate the health impact of HWT interventions16 and to supplement self-
reported health outcome data. In addition, the use of culture and PCR-based methods for Giardia 
detection are only useful to identify current and active episodes, and serological studies may be 
useful in not only detecting active giardiasis cases but in linking previous Giardia infection, 
determined by serological evidence, to other long-term health outcomes, such as intestinal 
enteropathy.46 Notably, GEMS found that stool-positive Cryptosporidium infection in children 
aged 12–23 months with moderate-to-severe diarrhea (the same age range as children at follow-
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up in this study) nearly tripled the risk of death between their enrollment and follow-up 
periods31; this indicates the potential of C. parvum seroconversion to be an indicator of early 
childhood mortality, which is an association that can be explored longitudinally using a larger 
study population. Since diarrheal disease in children throughout sub-Saharan Africa generally 
peaks between 6 and 11 months of age,47 demonstrated in the baseline analysis of our study,48 
children are not becoming infected with Salmonella during this crucial age window. 
IgG antibody responses to ETEC, Vibrio cholerae, C. jejuni, and norovirus were not 
associated with diarrheal disease, which is likely due to the relatively short duration of 
symptomatic illness relative to the 7- to 10-day delay in the development of a primary IgG 
antibody response. This may indicate a need for longitudinal follow-up in shorter intervals in a 
similar population of children to record diarrheal disease closer to the time of infection or further 
from the onset of symptoms, given the short-term acute cases of diarrhea associated with these 
pathogens and the length of time required to develop an IgG response. Diarrheal disease 
attributed to protozoa, particularly Giardia species, can lead to persistent infection and duodenal 
inflammation,49 which may explain why associations between serological evidence of previous 
infection is associated with 1-week prevalence of diarrhea. 
There were limitations in the design of this study that may affect the interpretation of these 
results. It is rare for HWT interventions to be blinded in RCTs for practical purposes, and this 
lack of blinding can lead to substantial reporting bias in which usage of the intervention and the 
intervention’s effect on diarrheal disease are exaggerated.11 Although this seroconversion study 
seeks to contribute an objective health indicator, it is still being compared with caregiver-
reported diarrheal disease, which is subject to bias. Another challenge in assessing water quality 
interventions is inconsistent intervention uptake.50 Among children in intervention households, 
23.6% were reported to have consumed some unfiltered water in the previous 24 hours; however, 
this study used an intention-to-treat analysis to conservatively assess health impact in light of 
expected imperfect uptake, and water quality characteristics were well balanced between study 
arms for both the children enrolled in this substudy (Table 1) and in the larger CRT,25 enabling 
more direct attribution of the intervention effects to the water filter itself. 
Statistical- and assay-based limitations in this study involved our limited sample size, 
imputation methods, and cutoff determination for seropositivity. This serological study itself was 
exploratory and nested within a broader CRT, and therefore our study power for this particular 
nested study was limited by the logistical considerations of the larger CRT. Further complicating 
this, 36.5% of our baseline blood samples was lost due to quality issues, which we sought to 
address through multiple imputation methods to account for potential bias attributed to sample 
loss. In addition, the determination of firm cutoff points for seropositivity is inherently 
problematic, as some children may be misclassified as seropositive or seronegative on either side 
of the cutoff point. Cutoff points were assigned in this study using available data for C. parvum, 
Giardia, E. histolytica, and T. gondii antigens, whereas cutoffs points were assigned using 
mixture models for the antigens of the other enteropathogens examined in this study. Future 
studies may enable the establishment of firmer cutoff points, but in the meantime, analyses of 
dichotomized data should be supplemented with continuous analyses to avoid spurious 
associations. Although primary analyses involved only observed data, data were imputed for the 
purposes of comparison to correct for bias attributed to missing data in secondary analyses. 
Multiple imputation assumes that data are missing at random, but children who were lost to 
follow-up due to illness or caregiver refusals may differ from children who were lost to follow-
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up for other reasons. That said, caregiver refusals and childhood illnesses were rare at follow-up, 
and balanced between intervention and control groups when they occurred. 
Finally, surveillance data on strain-specific circulation of enteropathogens in this region are 
limited. Antibody responses to potential circulating strains of Cryptosporidium are likely cross-
reactive with the C. parvum antigens used on our multiplex panel18 and the region of Giardia 
VSPs used on our panel is highly conserved among human-infecting assemblages; however, little 
is known about cross-reactivity of C. jejuni antigens with other strains of Campylobacter. 
Norovirus strains specific to this region and study period were also not known, so we included 
all available VLPs from three different norovirus strains (Norwalk, Sydney, and St. Cloud) to 
account for this limitation. The EtxB and CtxB used for this analysis are homologous proteins, 
thereby limiting our ability to independently attribute serological response to either ETEC or V. 
cholerae. Of note, however, EtxB is generally more immunostimulatory than CtxB,51 which 
appears to be consistent with results from our study. A systematic way of differentiating between 
the serological response to both pathogens is likely not possible; therefore, interpretations at this 
time should be made with regard to exposure to the toxin itself rather than the causal pathogens. 
Although bead-based rotavirus immunoassay methods have not yet been developed, rotavirus 
is vitally important to consider as a cause of diarrhea in children under 2 years old. Rotavirus-
attributable incidence of moderate-to-severe diarrhea among children in this age group far 
outpaced that of other pathogens in the GEMS study.15 It should be noted, though, that among 
children eligible for enrollment in this study at baseline, only 4.1% of children had not initiated 
their course of rotavirus vaccines, whereas 81.0% of children had received all three doses of 
rotavirus vaccine, as confirmed by examining the vaccination cards of all children enrolled in the 
RCT. Rotavirus immunoassay methods used in future WASH trials should be exclusive of the 
viral glycoproteins targeted by the vaccine. 
There is also a possibility of biological interactions between the enteropathogens included in 
these analyses; infection with one pathogen may either exacerbate or attenuate the risk of 
infection with another pathogen.52 More holistic approaches, such as factor analyses and scoring, 
may contribute to the body of knowledge of the joint epidemiologic and pathogenic associations 
between organisms in coinfection scenarios, particularly where opposing effects of the 
intervention are suggested. 
Finally, we cannot make temporal inferences regarding the timing of infection with respect to 
either diarrheal disease or receipt of the intervention; however, inferences for timing of 
seroconversion with regard to the intervention are generally better, as households typically 
received the intervention within a couple of weeks of the initial baseline visit. Longitudinal 
follow-up with shorter follow-up rounds could have provided the opportunity to capture diarrheal 
disease closer to the time of infection, which may have provided richer data regarding pathogens 
that are associated with acute episodes of diarrhea, such as norovirus and Campylobacter. 
Frequent longitudinal collection may also provide a more thorough assessment of age-specific 
prevalence of individual pathogens. 
CONCLUSION 
This study suggests that the water filter intervention was effective in reducing seroprevalence 
of C. parvum antibody responses at follow-up. Diarrheal disease within 7 days of sample 
collection appeared to be associated with IgG antibody responses to protozoan pathogens only. 
Acute infections caused by other pathogens on the panel may cause diarrhea, but this association 
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may not be detected using serologic antibody detection methods without more frequent sampling 
intervals. Postponing exposure to these pathogens even for 6 months is important; in our study 
population, diarrhea prevalence peaked between 12 and 18 months of age48 and early childhood 
diarrhea in general predicts downstream wasting, stunting, and excess mortality.6,7,53 
This study also suggests that serological testing of pathogen-specific antibodies can provide 
both measures of WASH intervention effectiveness and markers of recent diarrheal disease. 
Children who are 6–12 months of age at baseline and who can be followed for 6–12 months after 
intervention deployment comprise the ideal population for WASH seroconversion studies in this 
region. Longitudinal intervention studies involving larger populations and repeated sampling 
would provide richer data that would enable further assessment of the utility of these serological 
approaches to evaluating WASH interventions. 
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FIGURE 1. Sample flow from the enrollment to analysis stages for all children enrolled in the baseline and follow-up 
rounds of this study. Children were only eligible for blood draw during follow-up if they were initially enrolled 
during the baseline round. 
FIGURE 2. Median immunoglobulin responses, measured by median fluorescence intensity (MFI) to enteric antigens 
of interest at baseline and follow-up in intervention and control groups. 
FIGURE 3. Age-specific median immunoglobulin responses by age group among children 6–24 months old against 
(A) norovirus, (B) bacterial pathogens, such as Enterotoxigenic Escherichia coli, Vibrio cholerae, and 
Campylobacter jejuni, (C) Cryptosporidium parvum antigens, and (D) other protozoa, such as Giardia intestinalis, 
Entamoeba histolytica, and Toxoplasma gondii. 
FIGURE 4. Box plots of age-specific prevalence of serological responses by age group among children 6–24 months 
old against Giardia intestinalis (A) variant-specific surface protein AS8/GST fusion (VSP3) and (B) variant-specific 
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surface protein 42e/GST fusion (VSP5) antigens, represented as log of the median fluorescence intensity with 
background subtracted. 
TABLE 1 
Child and household characteristics among children enrolled in this serological substudy, disaggregated by study 
arm 
Characteristics Intervention (N = 75) count (%) 
Control (N = 
114) count (%)
Total (N = 189) 
count (%) 
Female 40 (53.3) 54 (47.4) 94 (49.7) 
Age at enrollment (months) 
 6 1 (1.5) 1 (1.0) 2 (1.2) 
 7–8 22 (32.4) 36 (35.6) 58 (34.3) 
 9–10 18 (26.5) 38 (37.6) 56 (33.1) 
 11–12 27 (39.7) 26 (25.7) 53 (31.4) 
Socioeconomic status* 
 Lowest 10 (13.3) 18 (15.8) 28 (14.8) 
 Second lowest 11 (14.5) 20 (17.5) 31 (16.4) 
 Middle 14 (18.7) 26 (22.8) 40 (21.2) 
 Second highest 21 (28.0) 27 (23.7) 48 (25.4) 
 Highest 19 (25.3) 23 (20.2) 42 (22.2) 
Time between rounds (months) 
 6–7 1 (1.5) 0 1 (0.6) 
 8–9 31 (46.3) 69 (67.0) 100 (58.8) 
 10–12 35 (52.2) 34 (33.0) 69 (40.6) 
Primary water source 
 Piped water into dwelling or 
plot 1 (1.3) 0 1 (0.5) 
 Hand pump/borehole 18 (24.0) 30 (26.6) 48 (25.5) 
 Protected spring/well 40 (53.3) 54 (47.8) 94 (50.0) 
 Unprotected spring/well 13 (17.3) 20 (17.7) 33 (17.6) 
 Surface water 3 (4.0) 9 (8.0) 12 (6.4 
Toilet type 
 Pit latrine with slab 24 (33.8) 35 (34.0) 59 (33.9) 
 Pit latrine with no slab 45 (63.4) 60 (58.3) 105 (60.3) 
 Ventilated pit latrine 0 3 (2.9) 3 (1.7) 
 Composting toilet 2 (2.8) 5 (4.9) 7 (4.0) 
Feces within 1 M of toilet 31 (41.3) 41 (36.0) 72 (38.1) 
Shared sanitation 24 (32.0) 27 (24.6) 51 (27.8) 
* Socioeconomic status quintile determined through polychoric principal components analysis, as described in the 
supplement. 
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TABLE 2 
Comparison of median MFI values with background subtracted (MFI-bg) at follow-up (N = 152), and the change in 
MFI-bg (MFI-bg) from baseline to follow-up (N = 97) compared between children in intervention (LFS) and 
control households with a paired t test 
 Intervention (N = 62) 
Control (N = 
91)   
Intervention 
(N = 34) 
Control (N = 
63)   
Antigen
* 
Median 
(Q1,Q3) follow-
up MFI-bg† 
Median 
(Q1,Q3) follow-
up MFI-bg 
 t (P value) 
Median 
(Q1,Q3)  
MFI-bg† 
Median 
(Q1,Q3)  
MFI-bg 
 t (P value) 
Cryptosporidium parvum 
 CpP2 
(100) 
11 (7,15) 10 (7,15) 0.05
1 
0.50 
(0.617) 
3 (2,9) 3 (3,6) 0.04
1 
0.25 
(0.800) 
 Cp17 438 (35,3303) 1,043 
(195,6,661) 
0.8
63 
2.00 
(0.047) 
371 
(34,3,283) 
763 (13,5,427) 0.6
17 
0.97 
(0.334) 
 Cp23 504 (69,4307) 2,024 
(167,8,404) 
0.5
42 
1.26 
(0.209) 
317 
(34,3,484) 
1,025 
(24,7,666) 
0.1
60 
0.27 
(0.786) 
Salmonella 
 LPS-B 10 (5,37) 5 (3,16) 0.42
1 
1.59 
(0.115) 
7 (1,36) 2 (2,13) 0.56
6 
1.51 
(0.136) 
 LPS-D 6 (4,12) 4 (3,8) 0.37
6 
1.94 
(0.055) 
1.5 (0,11) 1 (1,4) 0.55
6 
1.82 
(0.072) 
Norovirus 
 
Norwalk 
286 (36, 4295) 270 (24,1,866) 0.23
9 
0.49 
(0.625) 
37 
(35,1,168) 
85 (11,1,595) 0.0
66 
0.10 
(0.919) 
 
Sydney 
220 (43,903) 532 (128,1,374) 0.4
24 
1.18 
(0.240) 
122 (6,624) 375 (4,992) 0.4
30 
0.93 
(0.356) 
 St. 
Cloud 
54.5 (17,136) 53 (19,207) 0.0
78 
0.31 
(0.757) 
42 (8,109) 38 (3,185) 0.0
20 
0.05 
(0.957) 
Toxoplasma gondii 
 SAG2 5 (3,8) 5 (3,8) 0.04
8 
0.38 
(0.703) 
3 (0,7) 2 (2,5) 0.32
0 
1.23 
(0.221) 
Campylobacter jejuni 
 p18 960.5 
(174,5268) 
1,073 
(152,6,740) 
0.08
3 
0.22 
(0.827) 
858 
(1,5,806) 
387 
(18,7,769) 
0.55
9 
0.99 
(0.323) 
ETEC = Enterotoxigenic Escherichia coli; MFI = median fluorescent intensity; VSP3 = variant-specific surface 
protein AS8/GST fusion; VSP5 = variant-specific surface protein 42e/GST fusion. Linear regression was performed 
using log-transformed MFI-bg values. 
* Unable to transform MFI values for Giardia VSP3 and VSP5, ETEC EtxB, Vibrio cholera CtxB, Campylobacter 
p39, and Entamoeba histolytica LecA. Refer to Tables 2 and 3 utilizing cutoff values for seropositivity. 
† Mean fluorescence intensity values can range from 1 to 32,766 without background subtracted, but MFI values 
with background values subtracted (MFI-bg) can be negative.22 
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TABLE 3 
Crude and adjusted risk ratios comparing Round 2 seroprevalence among children in the intervention (LFS) and 
control groups who were 6–12 months old at enrollment 
Pathogen Antigen1 
Cutof
f 
(MFI
-bg) 
Method to 
establish 
cutoff 
Intervention 
(N = 62) 
crude 
seroprevalenc
e 
Control (N = 
90) crude 
seroprevalen
ce 
Crude RR (95% 
CI, P value) 
Adjusted RR 
(95% CI, P 
value) 
Giardia 
intestinalis 
VSP3 + 
VSP5 
  26 (0.4194) 28 (0.3111) 1.36 (0.91–2.02, 
0.135) 
1.40 (0.94–2.08, 
0.094) 
 VSP3 358 Mean + 
3SD 
26 (0.4194) 30 (0.3333) 1.27 (0.85–1.89, 
0.247) 
1.30 (0.88–1.93, 
0.186) 
 VSP5 233 Mean + 
3SD 
26 (0.4194) 28 (0.3111) 1.36 (0.91–2.02, 
0.135) 
1.40 (0.94–2.08, 
0.094) 
Cryptosporidiu
m parvum 
Cp17 + 
Cp23 
  23 (0.3710) 50 (0.5556) 0.67 (0.46–0.97, 
0.035) 
0.62 (0.44–0.89, 
0.010) 
 Cp17 259 ROC 32 (0.5161) 64 (0.7111) 0.73 (0.55–0.96, 
0.027) 
0.69 (0.52–0.92, 
0.010) 
 Cp23 662 ROC 30 (0.4839) 53 (0.5889) 0.83 (0.61–1.13, 
0.233) 
0.78 (0.58–1.04, 
0.094) 
Campylobacte
r jejuni 
p18 + 
p39 
  37 (0.5968) 50 (0.5556) 1.08 (0.81–1.44, 
0.594) 
1.00 (0.76–1.32, 
0.995) 
 p18 276 Mixture 
model 
38 (0.6129) 52 (0.5778) 1.07 (0.82–1.40, 
0.617) 
1.06 (0.81–1.39, 
0.653) 
 p39 74 Mixture 
model 
45 (0.7258) 63 (0.7000) 1.04 (0.85–1.27, 
0.782) 
1.00 (0.82–1.23, 
0.975) 
Norovirus 
(Norwalk) 
VLP 84 Mixture 
model 
28 (0.4242) 39 (0.4105) 0.97 (0.71–1.34, 
0.873) 
0.84 (0.62–1.14, 
0.268) 
Norovirus 
(Sydney) 
VLP 156 Mixture 
model 
21 (0.3387) 44 (0.4889) 0.66 (0.45–0.98, 
0.039) 
0.63 (0.44–0.90, 
0.012) 
Norovirus (St. 
Cloud) 
VLP 19 Mixture 
model 
26 (0.4267) 45 (0.3947) 1.06 (0.74–1.51, 
0.749) 
0.94 (0.70–1.27, 
0.708) 
Entamoeba 
histolytica 
LecA 302 Mean + 
3SD 
6 (0.0968) 7 (0.0778) 1.24 (0.44–3.52, 
0.686) 
1.42 (0.48–4.15, 
0.523) 
ETEC EtxB 1547
4 
Mixture 
model 
53 (0.8548) 72 (0.8000) 1.08 (0.91–1.27, 
0.392) 
1.11 (0.94–1.30, 
0.211) 
Vibrio cholera CtxB 9882 Mixture 
model 
55 (0.8871) 77 (0.8556) 1.05 (0.91–1.19, 
0.519) 
1.08 (0.94–1.23, 
0.274) 
CI = confidence interval; CtxB = cholera toxin  subunit; ETEC = Enterotoxigenic Escherichia coli; EtxB = ETEC 
heat-labile toxin  subunit; LeCA = lectin heavy chain subunit; MFI-bg = median fluorescent intensity values with 
background subtracted; RR = relative risk; ROC = receiver operating characteristic; SD = standard deviation; VLP = 
virus-like particle; VSP3 = variant-specific surface protein AS8/GST fusion; VSP5 = variant-specific surface protein 
42e/GST fusion. These data incorporate observed values only; samples deemed insufficient at the time of analysis 
were not included. Log-binomial models were run with robust variance estimation. Significant results (at  = 0.05) 
are highlighted with bold text. 
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TABLE 4 
Crude and adjusted risk ratios comparing Round 2 seroprevalence among children in the intervention (LFS) and 
control groups who were 6–12 months old and seronegative at enrollment, using observed data only 
Pathogen Antigen1 
Cuto
ff 
(MF
I-bg) 
Method to 
establish 
cutoff 
Intervention 
crude 
seroprevalen
ce 
Control 
crude 
seroprevalen
ce 
Crude RR (95% 
CI, P value) 
Adjusted RR 
(95% CI, P 
value) 
Giardia 
intestinalis 
VSP3 + 
VSP5 
  11/33 
(0.3333) 
14/59 
(0.2373) 
1.45 (0.80–2.69, 
0.219) 
1.46 (0.79–2.71, 
0.228) 
 VSP3 358 Mean + 
3SD 
11/33 
(0.3333) 
15/59 
(0.2542) 
1.37 (0.75–2.49, 
0.304) 
1.37 (0.75–2.52, 
0.305) 
 VSP5 233 Mean + 
3SD 
11/33 
(0.3333) 
14/59 
(0.2373) 
1.46 (0.79–2.69, 
0.219) 
1.46 (0.79–2.71, 
0.228) 
Cryptosporidiu
m parvum 
Cp17 + 
Cp23 
  9/27 
(0.3333) 
27/51 
(0.5294) 
0.64 (0.35–1.15, 
0.133) 
0.59 (0.33–1.07, 
0.082) 
 Cp17 259 ROC 15/27 
(0.5556) 
34/53 
(0.6415) 
0.88 (0.61–1.26, 
0.474) 
0.90 (0.61–1.32, 
0.577) 
 Cp23 662 ROC 14/32 
(0.4375) 
29/52 
(0.5577) 
0.83 (0.52–1.32, 
0.433) 
0.76 (0.48–1.21, 
0.252) 
Campylobacte
r jejuni 
p18 + p39   12/25 
(0.4800) 
17/34 
(0.5000) 
0.99 (0.62–1.56, 
0.950) 
0.83 (0.52–1.32, 
0.425) 
 p18 276 Mixture 
model 
15/26 
(0.5769) 
21/36 
(0.5833) 
1.06 (0.76–1.50, 
0.722) 
1.06 (0.81–1.39, 
0.653) 
 p39 74 Mixture 
model 
16/26 
(0.6154) 
28/42 
(0.6667) 
0.85 (0.59–1.22, 
0.379) 
0.81 (0.56–1.16, 
0.253) 
Norovirus 
(Norwalk) 
VLP 84 Mixture 
model 
6/32 
(0.1875) 
20/49 
(0.4082) 
0.43 (0.18–1.02, 
0.055) 
0.45 (0.19–1.10, 
0.080) 
Norovirus 
(Sydney) 
VLP 156 Mixture 
model 
12/34 
(0.3529) 
25/56 
(0.4464) 
0.78 (0.45–1.34, 
0.367) 
0.77 (0.44–1.34, 
0.354) 
Norovirus (St. 
Cloud) 
VLP 19 Mixture 
model 
16/36 
(0.4444) 
25/56 
(0.4464) 
1.15 (0.79–1.66, 
0.471) 
0.99 (0.72–1.37, 
0.955) 
Entamoeba 
histolytica 
LecA 302 Mean + 
3SD 
4/33 
(0.1212) 
5/62 
(0.0806) 
1.54 (0.43–5.46, 
0.507) 
1.72 (0.45–6.55, 
0.424) 
ETEC EtxB 15,4
74 
Mixture 
model 
18/24 
(0.7500) 
31/45 
(0.6889) 
1.10 (0.81–1.50, 
0.537) 
1.10 (0.80–1.50, 
0.556) 
Vibrio cholera CtxB 9,88
2 
Mixture 
model 
14/20 
(0.7000) 
29/38 
(0.7632) 
0.94 (0.65–1.34, 
0.715) 
1.07 (0.78–1.46, 
0.692) 
CI = confidence interval; CtxB = cholera toxin  subunit; ETEC = Enterotoxigenic Escherichia coli; EtxB = ETEC 
heat-labile toxin  subunit; LeCA = lectin heavy chain subunit; MFI-bg = median fluorescent intensity values with 
background subtracted; RR = relative risk; ROC = receiver operating characteristic SD = standard deviation; VLP = 
virus-like particle; VSP3 = variant-specific surface protein AS8/GST fusion; VSP5 = variant-specific surface protein 
42e/GST fusion. Log-binomial models account for robust variance estimation. Significant results (at  = 0.05) are 
highlighted with bold text. 
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TABLE 5 
Association between serological response and 7-day diarrhea prevalence 
  Diarrhea prevalence 
Pathogen Antigen 
Serologic 
response 
present (%) 
Serologic 
response absent 
(%) 
Unadjusted RR 
(95% CI, P value) 
Adjusted RR 
(95%CI, P value) 
Giardia 
intestinalis 
VSP3 + 
VSP5 
16/59 (0.2712) 34/208 (0.1635) 1.66 (0.97–2.84, 
0.065) 
1.94 (1.04–3.63, 
0.038) 
 VSP3 17/61 (0.2787) 34/208 (0.1635) 1.70 (1.01–2.88, 
0.046) 
1.99 (1.08–3.69, 
0.029) 
 VSP5 16/59 (0.2712) 35/210 (0.1667) 1.63 (0.95–2.77, 
0.074) 
1.87 (0.99–3.53, 
0.054) 
Cryptosporidiu
m parvum 
Cp17 + 
Cp23 
19/86 (0.2209) 19/138 (0.1377) 1.60 (0.91–2.84, 
0.104) 
2.21 (1.09–4.50, 
0.029) 
 Cp17 29/118 
(0.2458) 
22/151 (0.1457) 1.69 (1.04–2.74, 
0.035) 
2.12 (1.21–3.73, 
0.009) 
 Cp23 22/99 (0.2222) 29/170 (0.1706) 1.30 (0.78–2.16, 
0.307) 
1.45 (0.82–2.58, 
0.205) 
Campylobacter 
jejuni 
p18 + p39 24/108 
(0.2222) 
19/115 (0.1652) 1.35 (0.78–2.33, 
0.289) 
1.44 (0.76–2.74, 
0.267) 
 p18 25/118 
(0.2119) 
26/151 (0.1722) 1.23 (0.76–2.00, 
0.401) 
1.30 (0.77–2.19, 
0.321) 
 p39 31/144 
(0.2153) 
20/125 (0.1600) 1.35 (0.79–2.28, 
0.269) 
1.40 (0.76–2.57, 
0.281) 
Norovirus 
(Norwalk) 
VLP 19/92 (0.2065) 32/177 (0.1808) 1.14 (0.95–1.37, 
0.625) 
1.19 (0.69–2.06, 
0.531) 
Norovirus 
(Sydney) 
VLP 14/73 (0.1918) 37/196 (0.1888) 1.02 (0.59–1.75, 
0.954) 
1.09 (0.59–2.03, 
0.779) 
Norovirus (St. 
Cloud) 
VLP 18/93 (0.1935) 33/176 (0.1875) 1.03 (0.65–1.63, 
0.892) 
1.08 (0.66–1.77, 
0.761) 
Entamoeba 
histolytica 
LecA 4/14 (0.2857) 47/255 (0.1843) 1.55 (0.66–3.53, 
0.313) 
1.48 (0.65–3.38, 
0.355) 
ETEC EtxB 32/153 
(0.2092) 
19/116 (0.1638) 1.28 (0.73–2.24, 
0.395) 
1.71 (0.80–3.66, 
0.168) 
Vibrio cholerae CtxB 35/174 
(0.2011) 
16/95 (0.1684) 1.19 (0.67–2.12, 
0.545) 
1.48 (0.75–2.89, 
0.257) 
CI = confidence interval; CtxB = cholera toxin  subunit; ETEC = Enterotoxigenic Escherichia coli; EtxB = ETEC 
heat-labile toxin  subunit; LeCA = lectin heavy chain subunit; RR = relative risk; VSP3 = variant-specific surface 
protein AS8/GST fusion; VLP = virus-like particle; VSP5 = variant-specific surface protein 42e/GST fusion. All 
adjusted models are adjusted for age and socioeconomic status. Significant results (at  = 0.05) are highlighted with 
bold text 
* Adjusted for age and socioeconomic status. 
SUPPLEMENTAL METHODS 
Cutoff values. 
Cutoff values were established for Toxoplasma surface antigen 2A gene/GST fusion 
(SAG2A), Giardia intestinalis variant-specific surface protein AS8/GST fusion and variant-
specific surface protein 42e/GST fusion, Cryptosporidium parvum Cp17 and Cp23, and 
Entamoeba histolytica lectin heavy chain subunit (LecA). A 2-fold serial dilution of the World 
Health Organization International Standard for anti-Toxoplasma IgG (NIBSC 01/600; 20 IU/mL) 
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was used to generate a standard curve for the SAG2A antibody response. A cutoff previously 
established using a panel of known positive and negative sera (Priest and others, Epidemiol. and 
Infect., 2015) was found to be equivalent to 4.0 IU/mL. This value equated to 507 median 
fluorescent intensity values with background subtracted (MFI-bg) units for the SeroMap beads 
used in the current study. For the two G. intestinalis VSPs, 81 adult U.S. citizens with no history 
of foreign travel were used and the highest 5% of values were dropped. Then, the remaining 
antibody responses were used to establish a cutoff at the mean plus 3 standard deviation (SD). 
For C. parvum Cp17 and Cp23, cutoff values were based on a receiver operating characteristic 
(ROC) curve based on Western blot data.1 For the Cp17 and Cp23 ROC curves, sera were 
obtained from the same 81 U.S. adults that were used for to obtain the VSP cutoff values. For 
Cp17, 44 adults were blot positive and 37 were blot negative; for Cp23, 60 were blot positive 
and 21 were blot negative. Finally, for LecA, 65 American adults with no history of foreign 
travel were used. The highest three responses were eliminated and the cutoff was established as 
the mean + 3SD.1 
To establish cutoffs for positive values for the seroconversion analysis of the remaining 
antigens, finite mixture models of two Gaussian distributions2 were created from the continuous 
MFI values using the Cutoff Finder program3 in the R statistical language.4 Cutoff points were 
determined at the intersection of the two probability distribution functions of the mixed 
distribution, and values were dichotomized above and below this cutoff point to determine 
seropositivity. Because of nearly uniform apparent negative values below the 90th percentile for 
Salmonella Group B & D LPS, Salmonella was dropped from subsequent analyses. Results were 
interpreted as the likelihood of a serological response above these assigned cutoff values. 
Imputation methods. 
Although raw data were used for the primary analyses, multiple imputation methods were 
used to impute missing seroprevalence data for all children who were enrolled in the study at 
baseline to account for bias contributed by sample loss. The multiple imputation procedure was 
used to impute values for samples that were deemed insufficient in the laboratory and for 
children who were lost to follow-up, and it applied predictors of diarrhea identified during the 
baseline assessment (exclusive breastfeeding, water source, toilet type, socioeconomic status, 
feces on or around the toilet, shared toilet, gender, and age) and all serological responses to 
adequately project co-occurring serological responses using a fully conditional specification 
(FCS) method that applies separate conditional distributions for each missing variable (Yuan, 
2014). Imputed binary variables for serological responses were calculated based on predictors of 
MFI using multivariate linear regression. Covariates associated with seroprevalence at   0.35 
were included in the FCS imputation models for serological responses against each enteric 
pathogen. Data were imputed to create 25 total imputed datasets6 and GEE parameter estimates 
with empirical standard errors were combined from the 25 imputed datasets to generate valid 
statistical inferences about the associations under study (Yuan, 2000). All analyses were run with 
both observed samples and imputed data, and analysis model covariates were derived directly 
from the models used for the regression imputations.8 
Principal components analysis using polychoric correlations. 
We collected data on a total of 17 discrete household asset and demographic variables that 
were not direct exposures of interest to create a socioeconomic index that could be divided into 
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wealth quintile using principal components analysis with an inputted polychoric correlation 
matrix. Four variables were dropped from consideration for inclusion since univariate analyses 
revealed a standard deviation (SD  1) and because the population was fairly homogenous across 
those variables ( 95%). The following variables remained in our PCA: household head 
education, primary cook education, electricity access, type of flooring, wall and roof materials, 
and ownership of a radio, mobile telephone, mattress, agricultural land, house, and cows. 
SUPPLEMENTAL TABLE 1 
Categorization of enrollment and sample loss issues at baseline 
Study arm 
Total 
number of 
children 
eligible 
Blood draw 
not 
successful 
Caregiver 
refused 
Child not 
at home 
Child too 
sick for 
blood draw 
Total number of 
children 
enrolled 
Intervention 111 1 (0.90%) 24 (21.62%) 10 
(9.01%) 
1 (0.90%) 75 (67.5%) 
Control 140 2 (1.43%) 19 (13.57%) 4 (2.86%) 1 (0.71%) 114 (81.43%) 
Total 251 3 (1.20%) 43 (17.13%) 13 
(5.58%) 
2 (0.80) 189 (75.30%) 
Assessment of sample acceptability for laboratory analysis (among samples collected) 
 N Sample insufficient Samples available for analysis 
Intervention 75 33 (44.00%) 42 (56.00%) 
Control 114 36 (31.58%) 78 (68.42%) 
Total 189 69 (36.51%) 120 (63.49%) 
SUPPLEMENTAL TABLE 2 
Categorization of enrollment and sample loss issues at follow-up 
Study arm 
Total 
number of 
children 
enrolled 
Blood draw 
not 
successful 
Caregiver 
refused 
Child not 
at home 
Child too 
sick for 
blood draw 
Total samples 
collected 
Intervention 75 0 1 (1.33%) 8 
(10.67%) 
4 (5.33%) 62 (82.67%) 
Control 114 1 (0.88%) 5 (4.39%) 12 
(10.53%) 
5 (4.39%) 91 (79.82%) 
Total 189 1 (0.53%) 6 (3.17%) 20 
(10.58%) 
9 (4.76%) 153 (80.95%) 
Assessment of sample acceptability for laboratory analysis (among samples collected) 
 N Sample insufficient Samples available for analysis 
Intervention 62 0 62 (100.00%) 
Control 91 1 (1.10%) 90 (98.90%) 
Total 153 1 (0.65%) 152 (99.35%) 
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SUPPLEMENTAL TABLE 3 
Child and household characteristics among children at follow-up in this serological substudy, disaggregated by study 
arm 
Characteristics Intervention (N = 62) count (%) 
Control (N = 90)
count (%) 
Total (N = 152) 
count (%) 
Female 35 (56.5) 42 (46.7) 77 (50.7) 
Age at follow-up (months) 
12–13 1 (1.6) 1 (1.1) 2 (1.3) 
14–16 10 (16.1) 16 (17.8) 26 (17.1) 
17–19 26 (41.9) 52 (57.8) 78 (51.3) 
20–22 20 (32.3) 19 (21.1) 39 (25.7) 
23–24 5 (8.1) 2 (2.2) 7 (4.6) 
Socioeconomic status 
Lowest 9 (14.5) 16 (17.8) 25 (16.5) 
Second lowest 10 (16.1) 15 (16.7) 25 (16.5) 
Middle 12 (19.4) 18 (20.0) 30 (19.7) 
Second highest 18 (29.0) 23 (25.6) 41 (27.0) 
Highest 13 (31) 18 (20.0) 31 (20.4) 
Time between rounds (months) 
6–7 1 (1.6) 0 1 (0.7) 
8–9 27 (44.3) 64 (71.1) 91 (60.3) 
10–12 33 (54.1) 26 (28.9) 59 (39.1) 
Primary water source 
Piped water into dwelling or plot 1 (1.6) 0 1 (0.7) 
Hand pump/borehole 13 (21.0) 25 (27.8) 28 (25.0) 
Protected spring/well 37 (59.7) 45 (50.0) 82 (54.0) 
Unprotected spring/well 10 (16.1) 14 (15.6) 24 (15.8) 
Surface water 1 (1.6) 6 (6.7) 7 (4.6) 
Toilet type 
Pit latrine with slab 19 (32.2) 26 (31.7) 45 (31.9) 
Pit latrine with no slab 39 (66.1) 48 (58.5) 87 (61.7) 
Ventilated pit latrine 0 3 (3.7) 3 (2.1) 
Composting toilet 1 (1.7) 5 (6.1) 6 (4.3) 
Feces within 1 M of toilet 27 (43.6) 32 (35.6) 59 (38.8) 
Shared sanitation 21 (33.9) 20 (23.0) 41 (27.5) 
 
 
 
 
 
 
 
 
 
Page 25 of 30 
SUPPLEMENTAL TABLE 4 
Crude and adjusted risk ratios of imputed data comparing Round 2 seroprevalence and seroconversion among 
children in the intervention and control groups who were 6–12 months old 
Pathogen Antigen 
Cutof
f 
(MFI-
bg) 
Method to 
establish 
Cutoff 
Seroprevalence 
Crude RR (95% 
CI, P value) 
Seroprevalence 
adjusted RR 
(95% CI, P 
value) 
Seroconversion 
crude RR (95% 
CI, P value) 
Seroconversion 
adjusted RR 
(95% CI, P 
value) 
Giardia 
intestinalis 
VSP3 + 
VSP5 
  1.30 (0.85–
1.98, 0.229) 
1.32 (0.86–
2.01, 0.199) 
1.39 (0.87–
2.22, 0.163) 
1.41 (0.87–
2.22, 0.153) 
 VSP3 358 Mean + 
3SD 
1.24 (0.83–
1.85, 0.300) 
1.24 (0.82–
1.88, 0.317) 
1.31 (0.86–
2.01, 0.206) 
1.33 (0.87–
2.02, 0.186) 
 VSP5 233 Mean + 
3SD 
1.27 (0.85–
1.92, 0.246) 
1.30 (0.86–
1.97, 0.211) 
1.36 (0.87–
2.12, 0.174) 
1.38 (0.88–
2.15, 0.159) 
Cryptosporidiu
m parvum 
Cp17 + 
Cp23 
  0.68 (0.47–
0.97, 0.034) 
0.67 (0.47–
0.96, 0.027) 
0.66 (0.43–
1.02, 0.061) 
0.65 (0.43–
0.99, 0.044) 
 Cp17 259 ROC 0.73 (0.56–
0.96, 0.022) 
0.71 (0.54–
0.92, 0.011) 
0.76 (0.56–
1.04, 0.086) 
0.74 (0.55–
1.00, 0.052) 
 Cp23 662 ROC 0.85 (0.62–
1.16, 0.298) 
0.85 (0.63–
1.13, 0.254) 
0.83 (0.59–
1.17, 0.296) 
0.83 (0.60–
1.16, 0.281) 
Campylobacte
r jejuni 
p18 + 
p39 
  1.04 (0.82–
1.31, 0.750) 
1.07 (0.83–
1.39, 0.592) 
0.98 (0.82–
1.17, 0.806) 
0.99 (0.81–
1.22, 0.949) 
 p18 276 Mixture 
model 
1.07 (0.83–
1.39, 0.593) 
1.01 (0.77–
1.33, 0.928) 
1.08 (0.78–
1.50, 0.634) 
0.99 (0.69–
1.43, 0.967) 
 p39 74 Mixture 
model 
1.03 (0.85–
1.25, 0.771) 
1.02 (0.86–
1.24, 0.768) 
1.02 (0.77–
1.36, 0.864) 
1.04 (0.81–
1.33, 0.761) 
Norovirus 
(Norwalk) 
VLP 84 Mixture 
model 
1.01 (0.69–
1.47, 0.977) 
1.06 (0.73–
1.54, 0.764) 
0.85 (0.52–
1.37, 0.496) 
0.94 (0.57–
1.54, 0.797) 
Norovirus 
(Sydney) 
VLP 156 Mixture 
model 
0.72 (0.48–
1.08, 0.110) 
0.69 (0.47–
1.03, 0.070) 
0.78 (0.51–
1.20, 0.257) 
0.75 (0.49–
1.15, 0.184) 
Norovirus (St. 
Cloud) 
VLP 19 Mixture 
model 
1.08 (0.76–
1.53, 0.661) 
1.08 (0.77–
1.52, 0.666) 
1.18 (0.82–
1.72, 0.374) 
1.17 (0.81–
1.69, 0.413) 
Entamoeba 
histolytica 
LecA 302 Mean + 
3SD 
1.29 (0.47–
3.56, 0.624) 
1.28 (0.46–
3.60, 0.636) 
1.12 (0.38–
3.26, 0.838) 
1.06 (0.44–
2.55, 0.889) 
ETEC EtxB 15474 Mixture 
model 
1.07 (0.92–
1.24, 0.377) 
1.02 (0.88, 
1.18, 0.822) 
1.10 (0.91–
1.33, 0.335) 
1.03 (0.86–
1.23, 0.782) 
Vibrio 
cholerae 
CtxB 9882 Mixture 
model 
1.03 (0.91–
1.17, 0.577) 
1.04 (0.92–
1.19, 0.516) 
1.03 (0.84–
1.25, 0.796) 
1.03 (0.83–
1.28, 0.771) 
CI = confidence interval; CtxB = cholera toxin  subunit; ETEC = Enterotoxigenic Escherichia coli; EtxB = ETEC 
heat-labile toxin  subunit; LeCA = lectin heavy chain subunit; MFI-bg = median fluorescent intensity values with 
background subtracted; RR = relative risk; ROC = receiver operating characteristic SD = standard deviation; VLP = 
virus-like particle; VSP3 = variant-specific surface protein AS8/GST fusion; VSP5 = variant-specific surface protein 
42e/GST fusion. 
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SUPPLEMENTAL TABLE 5 
Adjusted models used to calculate the association between intervention status and Round 2 seroprevalence (SP) 
against any particular antigen 
Adjusted log-binomial models examining effect of intervention status on Round 2 seroprevalence 
Outcome Variables included in adjusted model 
Cp17 Intervention arm, shared sanitation 
Cp23 Intervention arm, shared sanitation 
Cp17 + 
Cp23 
Intervention arm, shared sanitation 
VSP3 Intervention arm, gender 
VSP5 Intervention arm, gender 
VSP3 + 
VSP5 
Intervention arm, gender 
Norwalk Intervention arm, shared sanitation 
Sydney Intervention arm, shared sanitation, age, water source 
St. Cloud Intervention arm, shared sanitation, age 
LecA Intervention arm, shared sanitation 
LPS-B Intervention arm, shared sanitation 
LPS-D Intervention arm, socioeconomic status and age 
Cp18 Intervention arm, water source 
Cp39 Intervention arm, shared sanitation 
Cp18 + 
Cp39 
Intervention arm, water source, shared sanitation 
EtxB Intervention arm, shared sanitation, toilet area cleanliness 
CtxB Intervention arm, breastfeeding status at baseline, age and gender 
CtxB = cholera toxin  subunit; EtxB = ETEC heat-labile toxin  subunit; LeCA = lectin heavy chain subunit; VSP3 
= variant-specific surface protein AS8/GST fusion; VSP5 = variant-specific surface protein 42e/GST fusion. All 
adjusted models measuring the association between seroprevalence (across both rounds) and diarrheal disease were 
adjusted by age and socioeconomic status and are not depicted in this table. 
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Figure 2 
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Figure 3 
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Figure 4 
 
 
 
